High risk — avoid this combination unless there is no good alternative.
Hyperkalemia, symptomatic hypotension (light-headedness, fainting on standing), and acute kidney injury. The ONTARGET trial found combining the two offered no cardiovascular benefit over either drug alone but caused significantly more adverse renal events.
Why this happens (mechanism)
Lisinopril (an ACE inhibitor) and losartan (an ARB) both block the renin-angiotensin system, just at different steps. Doubling up doesn't double the blood-pressure benefit but does double the side-effect load — high potassium, low blood pressure on standing, and worsening kidney function.
What to monitor
- Serum potassium and creatinine within 1-2 weeks of starting both
- Blood pressure (sitting AND standing) at every visit
- Symptoms of dizziness, fainting, muscle weakness (signs of hyperkalemia)
Dose adjustment
The combination is generally not recommended — choose either the ACE inhibitor or the ARB, not both. If a clinician has deliberately layered them (rare cases of resistant proteinuria), labs need monitoring at minimum every 1-2 weeks initially.
Safer alternatives to consider
Add-on antihypertensive that doesn't stack with the renin-angiotensin block.
Standard add-on with complementary, not overlapping, mechanism.
Different class entirely; useful when heart rate also needs control.
Always discuss alternatives with your prescriber before making any change. The right choice depends on your other medications, conditions, and what is working for you today.